Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

作者：Robert A. Smith, Dana N. Raugi, Robert S. Nixon, Moussa Seydi, Nicolas Margot, Christian Callebaut, Geoffrey S. Gottlieb, Fatima Sall, Khardiata Diallo, Mouhamadou Baïla Diallo, Khadim Faye, Samba Cisse, Fatou Simal, Marie Pierre Sy, Binetou Diaw, Ousseynou Ndiaye, Babacar Faye, Ndeye Astou Diop, Amadou Bale Diop, Marianne Fadiome, ElHadji Ibrahima Sall, Boubacar Kande, Jean Jacques Malomar, Ousseynou Cisse, Ibrahima Tito Tamba, Dominique Faye, Papa Amadou Diallo, Mamadou Habib Diop, Jean Phillippe Diatta, Adji Fatoumata Diene, François Badiane, Baboucar Diatta, Raphael Bakhoum, Aïssatou Barry, Aissatou Mamy Sané, Jacques F. Sambou, Bokeni Diedhiou, Sidy Diatta, Juliette Gomis, Terese Dieye, Stephen E. Hawes, Noelle A. Benzekri, John Lin, Ming Chang, Robert Coombs, James I. Mullins, Papa Salif Sow, Nancy B. Kiviat · 发表于：The Journal of Infectious Diseases · 年份：2023 · DOI：10.1093/infdis/jiad562 · 被引用次数：18 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、Cytomegalovirus and herpesvirus research

The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti-HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response.